原发性硬化性胆管炎
医学
基因型
胃肠病学
内科学
肿瘤科
生物
遗传学
基因
疾病
作者
Andreas Wannhoff,Johannes R. Hov,Trine Folseraas,Christian Rupp,Kilian Friedrich,Jarl Andreas Anmarkrud,Karl Heinz Weiss,Peter Sauer,Peter Schirmacher,Kirsten Muri Boberg,Wolfgang Stremmel,Tom H. Karlsen,Daniel Gotthardt
标识
DOI:10.1016/j.jhep.2013.08.005
摘要
Allelic variants of fucosyltransferases 2 and 3 (FUT2/3) influence serum levels of CA19-9, a screening parameter commonly used for detection of biliary malignancy in PSC. We aimed at improving diagnostic accuracy of CA19-9 by determining the impact of FUT2/3 genotypes.CA19-9 levels were measured in 433 PSC patients, 41 of whom had biliary malignancy. Genotypes for FUT3 and FUT2 were used to assign patients to one of three groups: A, no FUT3 activity regardless of FUT2 activity; B, both FUT2 and FUT3 activity and C, no FUT2 activity without loss of FUT3 activity. Group-specific cut-off values were determined by Youden's index.The median CA19-9 values of cancer-free patients were significantly different (p<0.001) in Groups A (2.0U/ml), B (17.0U/ml), and C (37.0U/ml). Biliary malignancy patients in Groups B and C had significantly higher CA19-9 values than cancer-free patients (p<0.001). The optimal cut-off, as determined by ROC analysis, for all patients was 88.5U/ml. Optimal cut-off values in Groups A, B, and C were 4.0U/ml, 74.5U/ml, and 106.8U/ml, respectively. Use of these values improved sensitivity of CA19-9 in Groups B and C. Further, use of group-dependent cut-off values with 90% sensitivity resulted in a 42.9% reduction of false positive results.Use of FUT2/3 genotype-dependent cut-off values for CA19-9 improved sensitivity and reduced the number of false positive results.
科研通智能强力驱动
Strongly Powered by AbleSci AI